This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia

This study has been terminated.
(This study was terminated on November 20, 2003 because of poor recruitment. This study was not terminated due to safety/efficacy.)
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00645515
First received: March 20, 2008
Last updated: April 25, 2008
Last verified: April 2008
  Purpose
The purpose of this study is to compare the safety of ziprasidone and risperidone for the treatment of chronic schizophrenia. The primary purpose is to differentiate the effects of ziprasidone and risperidone on extrapyramidal side effects and the secondary purpose is to compare their tolerability and efficacy.

Condition Intervention Phase
Schizophrenia Drug: Ziprasidone Drug: Risperidone Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Ziprasidone Versus Risperidone In The Treatment Of Chronic Schizophrenia: A Six Months, Double Blind Randomized, Parallel Group Study

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Change from baseline in Simpson-Angus Scale (SAS) scores at Weeks 1, 2, 3, 4, 6, 10, 12, 16, and 24 [ Time Frame: Day 1 and Weeks 1, 2, 3, 4, 6, 10, 12, 16, and 24 ]

Secondary Outcome Measures:
  • Change from baseline in cognitive function assessment at Weeks 4 and 24 [ Time Frame: Day 1 and Weeks 4 and 24 ]
  • Change from baseline in Patient Preference Scale (PPS) at Weeks 4, 10, 12, 16, and 24 [ Time Frame: Day 1 and Weeks 4, 10, 12, 16, and 24 ]
  • Changes in Sexual Functioning Questionnaire at Weeks 1, 4, 12, 16, and 24 [ Time Frame: Day 1 and Weeks 1, 4, 12, 16, and 24 ]
  • Change from baseline in Cuestionario Sevilla at Weeks 1, 4, 12, 16, and 24 [ Time Frame: Day 1 and Weeks 1, 4, 12, 16, and 24 ]
  • Change from baseline in Modified Resource Utilization Questionnaire (RUQ) scores at Weeks 3, 4, 6, 10, 12, 16, and 24 [ Time Frame: Day 1 and Weeks 3, 4, 6, 10, 12, 16, and 24 ]
  • Laboratory tests and electrocardiogram at Week 24 [ Time Frame: Screening and Week 24 ]
  • Adverse events on Day 1 and Weeks 1, 2, 3, 4, 6, 10, 12, 16, and 24 [ Time Frame: Day 1 and Weeks 1, 2, 3, 4, 6, 10, 12, 16, and 24 ]
  • Change from baseline in Clinical Global Impressions-Severity (CGI-S) scale scores at Weeks 1, 2, 3, 4, 6, 10, 12, 16, and 24 [ Time Frame: Day 1 and Weeks 1, 2, 3, 4, 6, 10, 12, 16, and 24 ]
  • Clinical Global Impressions-Improvement (CGI-I) scale scores at Weeks 1, 2, 3, 4, 6, 10, 12, 16, and 24 [ Time Frame: Day 1 and Weeks 1, 2, 3, 4, 6, 10, 12, 16, and 24 ]
  • Change from baseline in Positive and Negative Syndrome Scale (PANSS) total scores and negative subscale scores at Weeks 4, 10, 12, 16, and 24 [ Time Frame: Day 1 and Weeks 4, 10, 12, 16, and 24 ]
  • Barnes Akathisia Scale (BAS) and Abnormal Involuntary Movements Scale (AIMS) scores at Weeks 4, 10, 12, 16, and 24 [ Time Frame: Day 1 and Weeks 4, 10, 12, 16, and 24 ]

Estimated Enrollment: 240
Study Start Date: June 2003
Study Completion Date: December 2003
Arms Assigned Interventions
Experimental: Arm A Drug: Ziprasidone
Initial dose of 40 mg capsules twice daily on Days 1-3; dose could be flexibly changed within the range of 40 to 80 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
Other Name: Geodon, Zeldox
Active Comparator: Arm B Drug: Risperidone
Initial dose of 10 mg once daily on Days 1-3; dose could be flexibly changed within the range of 3 to 9 mg twice daily for the remainder of the study; treatment duration was 24 weeks.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of schizophrenia
  • CGI-S score of 4 or less at baseline

Exclusion Criteria:

  • Concurrent antipsychotic treatment
  • Treatment with antidepressants or mood stabilizers within 2 weeks of randomization
  • Acute exacerbation of schizophrenia within 3 months of baseline
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00645515

Locations
Spain
Pfizer Investigational Site
Bilbao, Vizcaya, Spain, 48010
Pfizer Investigational Site
Getxo, Vizcaya, Spain, 48990
Pfizer Investigational Site
Madrid, Spain, 28007
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00645515     History of Changes
Other Study ID Numbers: A1281065
Study First Received: March 20, 2008
Last Updated: April 25, 2008

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Risperidone
Ziprasidone
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents

ClinicalTrials.gov processed this record on July 25, 2017